Oncternal Therapeutics Inc expected to post a loss of 20  cents a share - Earnings Preview

Oncternal Therapeutics

04/05/2022 03:03

* Oncternal Therapeutics Inc  ONCT.OQ   ONCT.O  is expected
to show a fall in quarterly revenue when it reports  results on
May 5. 
    * The San Diego California-based  company is expected to
report  a
29.8% decrease in revenue to $525 thousand from $748 thousand a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Oncternal
Therapeutics
Inc is for a loss of 20 cents per share. For the same quarter
last year, the company reported a loss of 12 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 0.6%
in the last three months. ​
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $15​, above​ its last closing price
of $1.10. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.24       -0.25      -0.16     Beat    35
 Sep. 30 2021  -0.20       -0.16      -0.19     Missed  -18.7
 Jun. 30 2021  -0.14       -0.14      -0.16     Missed  -16.4​
 Mar. 31 2021  -0.10       -0.10      -0.12     Missed  -20
 ​​Dec.        -0.19       -0.18      -0.09     Beat    50
 31 2020                                                
 Sep. 30 2020  -0.30       -0.30      -0.22     Beat    26.7​
                                      -0.34             
                                      -0.31             
 This summary was machine generated May 4 at 02:02 GMT.  All
figures in US dollars  unless otherwise stated